Myelodysplastic Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2500
Buy Report View Sample

Published: November 30, 2022 Report Code: GDGMDHC22396IDB-ST

Select Item

Myelodysplastic Syndrome Pipeline Drugs Market Overview

Myelodysplastic syndrome (MDS) is a condition that affects the bone marrow and the blood cells it produces. The condition rarely causes signs or symptoms in the early stages of the disease. The symptoms include fatigue, shortness of breath, unusual paleness (pallor) due to anemia, easy or unusual bruising or bleeding, and frequent infections.

The Myelodysplastic Syndrome pipeline drugs market research report provides comprehensive information on the therapeutics under development for Myelodysplastic Syndrome (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myelodysplastic Syndrome and features dormant and discontinued projects.

Myelodysplastic Syndrome Pipeline Products Market Segmentation by Targets

The key targets in the Myelodysplastic Syndrome pipeline products market are Leukocyte Surface Antigen CD47, Cells Expressing Interleukin 3 Receptor Subunit Alpha, DNA (Cytosine 5) Methyltransferase 1, Receptor Type Tyrosine Protein Kinase FLT3, B Cell Lymphoma 2, CD3, Cells Expressing Myeloid Cell Surface Antigen CD33, Cells Expressing Wilms Tumor Protein, Isocitrate Dehydrogenase [NADP] Cytoplasmic, and Isocitrate Dehydrogenase [NADP] Mitochondrial, among others. Leukocyte Surface Antigen CD47 was the leading target in the pipeline.

Myelodysplastic Syndrome Pipeline Products Market Analysis by Targets

Myelodysplastic Syndrome Pipeline Products Market Analysis by Targets

For more target insights into the Myelodysplastic Syndrome pipeline products market, download a free report sample

Myelodysplastic Syndrome Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the Myelodysplastic Syndrome pipeline products market are Leukocyte Surface Antigen CD47 Inhibitor, Cytotoxic To Cells Expressing Interleukin 3 Receptor Subunit Alpha, DNA (Cytosine 5) Methyltransferase 1 Inhibitor, Receptor Type Tyrosine Protein Kinase FLT3 Inhibitor, B Cell Lymphoma 2 Inhibitor, CD3 Agonist, Cytotoxic To Cells Expressing Myeloid Cell Surface Antigen CD33, Cytotoxic To Cells Expressing Wilms Tumor Protein, Isocitrate Dehydrogenase [NADP] Cytoplasmic Inhibitor, and Isocitrate Dehydrogenase [NADP] Mitochondrial Inhibitor, among others. Leukocyte Surface Antigen CD47 Inhibitor is the leading MoA.

Myelodysplastic Syndrome Pipeline Products Market Analysis by Mechanisms of Action

Myelodysplastic Syndrome Pipeline Products Market Analysis by Mechanisms of Action

For more mechanisms of action insights into the Myelodysplastic Syndrome pipeline products market, download a free report sample

Myelodysplastic Syndrome Pipeline Products Market Segmentation by Routes of Administration

The key routes of administration in the Myelodysplastic Syndrome pipeline products market are intravenous, oral, parenteral, subcutaneous, intratumor, intravenous drip, intradermal, intraperitoneal, intraarticular, and intralesional, among others. Intravenous is the leading route for administration.

Myelodysplastic Syndrome Pipeline Products Market Analysis by Routes of Administration

Myelodysplastic Syndrome Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights into the Myelodysplastic Syndrome pipeline products market, download a free report sample

Myelodysplastic Syndrome Pipeline Products Market Segmentation by Molecule Types

The key molecule types in the Myelodysplastic Syndrome pipeline products market are small molecule, monoclonal antibody, cell therapy, gene-modified cell therapy, fusion protein, monoclonal antibody conjugated, subunit vaccine, antisense oligonucleotide, synthetic peptide, and antisense RNAi oligonucleotide, among others.

Myelodysplastic Syndrome Pipeline Products Market Analysis by Molecule Types

Myelodysplastic Syndrome Pipeline Products Market Analysis by Molecule TypesFor more molecule type insights into the Myelodysplastic Syndrome pipeline products market, download a free report sample

Myelodysplastic Syndrome Pipeline Products Market - Competitive Landscape

Some of the leading companies in the Myelodysplastic Syndrome pipeline products market are Bristol-Myers Squibb Co, Novartis AG, AstraZeneca Plc, Pfizer Inc, Johnson & Johnson, Arcellx Inc, Ascentage Pharma Group International, Astex Pharmaceuticals Inc, Cyclacel Pharmaceuticals Inc, and Innovent Biologics Inc. Bristol-Myers Squibb Co is the leading company in the Myelodysplastic Syndrome pipeline products market.

Myelodysplastic Syndrome Pipeline Products Market Analysis by Companies

Myelodysplastic Syndrome Pipeline Products Market Analysis by Companies

To know more about the leading players in the Myelodysplastic Syndrome pipeline products market, download a free report sample

Myelodysplastic Syndrome pipeline Products Market Report Overview

Key Targets Leukocyte Surface Antigen CD47, Cells Expressing Interleukin 3 Receptor Subunit Alpha, DNA (Cytosine 5) Methyltransferase 1, Receptor Type Tyrosine Protein Kinase FLT3, B Cell Lymphoma 2, CD3, Cells Expressing Myeloid Cell Surface Antigen CD33, Cells Expressing Wilms Tumor Protein, Isocitrate Dehydrogenase [NADP] Cytoplasmic, and Isocitrate Dehydrogenase [NADP] Mitochondrial
Key Mechanisms of Action Leukocyte Surface Antigen CD47 Inhibitor, Cytotoxic To Cells Expressing Interleukin 3 Receptor Subunit Alpha, DNA (Cytosine 5) Methyltransferase 1 Inhibitor, Receptor Type Tyrosine Protein Kinase FLT3 Inhibitor, B Cell Lymphoma 2 Inhibitor, CD3 Agonist, Cytotoxic To Cells Expressing Myeloid Cell Surface Antigen CD33, Cytotoxic To Cells Expressing Wilms Tumor Protein, Isocitrate Dehydrogenase [NADP] Cytoplasmic Inhibitor, and Isocitrate Dehydrogenase [NADP] Mitochondrial Inhibitor
Key Routes of Administration Intravenous, Oral, Parenteral, Subcutaneous, Intratumor, Intravenous Drip, Intradermal, Intraperitoneal, Intraarticular, and Intralesional
Key Molecule Type Small Molecule, Monoclonal Antibody, Cell Therapy, Gene-Modified Cell Therapy, Fusion Protein, Monoclonal Antibody Conjugated, Subunit Vaccine, Antisense Oligonucleotide, Synthetic Peptide, and Antisense RNAi Oligonucleotide
Leading Companies Bristol-Myers Squibb Co, Novartis AG, AstraZeneca Plc, Pfizer Inc, Johnson & Johnson, Arcellx Inc, Ascentage Pharma Group International, Astex Pharmaceuticals Inc, Cyclacel Pharmaceuticals Inc, and Innovent Biologics Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Myelodysplastic Syndrome (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Myelodysplastic Syndrome (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Myelodysplastic Syndrome (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Myelodysplastic Syndrome (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Myelodysplastic Syndrome (Oncology)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

  • Find and recognize significant and varied types of therapeutics under development for Myelodysplastic Syndrome (Oncology).

  • Classify potential new clients or partners in the target demographic.

  • Develop tactical initiatives by understanding the focus areas of leading companies.

  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

  • Formulate corrective measures for pipeline projects by understanding Myelodysplastic Syndrome (Oncology) pipeline depth and focus of Indication therapeutics.

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

A. Menarini Industrie Farmaceutiche Riunite Srl
AB Science SA
AbbVie Inc
Abfero Pharmaceuticals Inc
Acrotech Biopharma LLC
Actinium Pharmaceuticals Inc
ADC Therapeutics SA
Advanced BioDesign
Affimed GmbH
AIMM Therapeutics BV (Inactive)
Akeso Inc
Alaunos Therapeutics Inc
ALX Oncology Holdings Inc
Amgen Inc
Amphivena Therapeutics Inc
Angiocrine Bioscience Inc
Apogenix AG
Aprea Therapeutics Inc
AptaBio Therapeutics Inc
Aptevo Therapeutics Inc
Arcellx Inc
Argenx SE
Ascentage Pharma Group International
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Aucentra Therapeutics Pty Ltd
Aurigene Discovery Technologies Ltd
Bayer AG
BeiGene Ltd
Beijing Mabworks Biotech Co Ltd
Bellicum Pharmaceuticals Inc
BerGenBio ASA
Bio-Path Holdings Inc
BioLineRx Ltd
BioMed Valley Discoveries Inc
BioSight Ltd
BioTheryX Inc
BlueSphere Bio Inc
Bristol-Myers Squibb Co
Calithera Biosciences Inc
Captor Therapeutics SA
CellCentric Ltd
Cellenkos Inc
Cellerant Therapeutics Inc
Celularity Inc
Celyad Oncology SA
Center for Genetic Engineering and Biotechnology
CheckPoint Immunology Inc
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Chimeric Therapeutics Ltd
Chimerix Inc
China NT Pharma Group Co Ltd
Chordia Therapeutics Inc
Cleave Therapeutics Inc
Cornerstone Pharmaceuticals Inc
CrystalGenomics Inc
Cullinan Oncology Inc
Cyclacel Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Delta-Fly Pharma Inc
Denovo Biopharma LLC
Deverra Therapeutics Inc
Diatheva srl
DiNonA Inc
Disc Medicine Inc
Eisai Co Ltd
Eli Lilly and Co
Ellipses Pharma Ltd
Escend Pharmaceuticals Inc
ExCellThera Inc
Faron Pharmaceuticals Oy
Fate Therapeutics Inc
Forma Therapeutics Inc
Fujifilm Holdings Corp
Gadeta BV
Gamida Cell Ltd
GeneScience Pharmaceuticals Co Ltd
Geron Corp
Gilead Sciences Inc
GSK plc
GT Biopharma Inc
Guangzhou Diqi Pharmaceutical Technology Co Ltd
Hangzhou Bensheng Pharmaceutical Co Ltd
Hangzhou Zede Pharmaceutical Technology Co Ltd
HEC Pharma Co Ltd
Helocyte Biosciences Inc
HemoGenyx Pharmaceuticals Plc
Horizon Therapeutics Plc
Hutchison MediPharma Ltd
HUYA Bioscience International LLC
I-Mab
iCell Gene Therapeutics LLC
IGM Biosciences Inc
Imago BioSciences Inc
Immune System Key Ltd
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
ImmunityBio Inc
ImmunoGen Inc
IN8bio Inc
Incyte Corp
Inmune Bio Inc
Innate Pharma SA
Innovent Biologics Inc
Jasper Therapeutics Inc
Jazz Pharmaceuticals Plc
Jiangsu Hengrui Medicine Co Ltd
Jiangsu Lianhuan Pharmaceutical Co Ltd
Johnson & Johnson
Jubilant Therapeutics Inc
KAHR medical Ltd
Kangpu Biopharmaceuticals Ltd
Karyopharm Therapeutics Inc
Kiadis Pharma NV
Kintor Pharmaceutical Ltd
Kurome Therapeutics Inc
LegoChem Biosciences Inc
Les Laboratoires Servier SAS
Leukos Biotech SL
Lixte Biotechnology Holdings Inc
Mabwell Shanghai Bioscience Co Ltd
MacroGenics Inc
Mana Therapeutics Inc
Marker Therapeutics Inc
Maxinovel Pharmaceuticals
MediGene AG
MedPacto Inc
MEI Pharma Inc
Mendus AB
Merck & Co Inc
Millennium Pharmaceuticals Inc
Molecular Partners AG
Molecular Templates Inc
MorphoSys AG
Nemucore Medical Innovations Inc
Newave Pharmaceutical Inc
Nkarta Inc
Nohla Therapeutics Inc
Novartis AG
Ohara Pharmaceutical Co Ltd
Oncoheroes Biosciences Inc
Onconova Therapeutics Inc
Oncotelic Therapeutics Inc
Ono Pharmaceutical Co Ltd
Orca Biosystems Inc
Otsuka Pharmaceutical Co Ltd
Oxcia AB
PersImmune Inc
Pfizer Inc
Pharma Mar SA
Pharmaxis Ltd
Pinotbio Inc
Plexxikon Inc
Prelude Therapeutics Inc
QLSF Biotherapeutics Inc
Race Oncology Ltd
Rigel Pharmaceuticals Inc
Roivant Sciences Ltd
Ryvu Therapeutics SA
Salarius Pharmaceuticals Inc
Seagen Inc
SELLAS Life Sciences Group Inc
Shattuck Labs Inc
Shorla Pharma Ltd
Silence Therapeutics Plc
Sino Biopharmaceutical Ltd
SiNOPSEE Therapeutics Pte Ltd
Smart Immune SAS
Stelexis Therapeutics LLC
Suzhou JiSheng Pharmaceutical Co Ltd
Syntrix Pharmaceuticals
Syros Pharmaceuticals Inc
Tacitus Therapeutics Inc
Takara Bio Inc
TC BioPharm Ltd
Teva Pharmaceutical Industries Ltd
Toko Pharmaceutical Industries Co Ltd
TOT Biopharm Co Ltd
Treadwell Therapeutics Inc
Trethera Corp
TScan Therapeutics Inc
Vincerx Pharma Inc
Vyriad Inc
Wugen Inc
Xencor Inc
Zhengda Tianqing Pharmaceutical Group Co Ltd
Zydus Lifesciences Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Myelodysplastic Syndrome – Overview

Myelodysplastic Syndrome – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Myelodysplastic Syndrome – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Myelodysplastic Syndrome – Companies Involved in Therapeutics Development

Myelodysplastic Syndrome – Drug Profiles

Myelodysplastic Syndrome – Dormant Projects

Myelodysplastic Syndrome – Discontinued Products

Myelodysplastic Syndrome – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Myelodysplastic Syndrome, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Myelodysplastic Syndrome – Dormant Projects, 2022

Myelodysplastic Syndrome – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Myelodysplastic Syndrome, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

  • What are the key targets in the Myelodysplastic Syndrome pipeline products market?

    The key targets in the Myelodysplastic Syndrome pipeline products market are Leukocyte Surface Antigen CD47, Cells Expressing Interleukin 3 Receptor Subunit Alpha, DNA (Cytosine 5) Methyltransferase 1, Receptor Type Tyrosine Protein Kinase FLT3, B Cell Lymphoma 2, CD3, Cells Expressing Myeloid Cell Surface Antigen CD33, Cells Expressing Wilms Tumor Protein, Isocitrate Dehydrogenase [NADP] Cytoplasmic, and Isocitrate Dehydrogenase [NADP] Mitochondrial, among others.

  • What are the key mechanisms of action in the Myelodysplastic Syndrome pipeline products market?

    The key mechanisms of action in the Myelodysplastic Syndrome pipeline products market are Leukocyte Surface Antigen CD47 Inhibitor, Cytotoxic To Cells Expressing Interleukin 3 Receptor Subunit Alpha, DNA (Cytosine 5) Methyltransferase 1 Inhibitor, Receptor Type Tyrosine Protein Kinase FLT3 Inhibitor, B Cell Lymphoma 2 Inhibitor, CD3 Agonist, Cytotoxic To Cells Expressing Myeloid Cell Surface Antigen CD33, Cytotoxic To Cells Expressing Wilms Tumor Protein, Isocitrate Dehydrogenase [NADP] Cytoplasmic Inhibitor, and Isocitrate Dehydrogenase [NADP] Mitochondrial Inhibitor, among others.

  • What are the key routes of administration in the Myelodysplastic Syndrome pipeline products market?

    The key routes of administration in the Myelodysplastic Syndrome pipeline products market are intravenous, oral, parenteral, subcutaneous, intratumor, intravenous drip, intradermal, intraperitoneal, intraarticular, and intralesional, among others.

  • What are the key molecule types in the Myelodysplastic Syndrome pipeline products market?

    The key molecule types in the Myelodysplastic Syndrome pipeline products market are small molecule, monoclonal antibody, cell therapy, gene-modified cell therapy, fusion protein, monoclonal antibody conjugated, subunit vaccine, antisense oligonucleotide, synthetic peptide, and antisense RNAi oligonucleotide, among others.

  • Which are the leading companies in the Myelodysplastic Syndrome pipeline products market?

    Some of the leading companies in the Myelodysplastic Syndrome pipeline products market are Bristol-Myers Squibb Co, Novartis AG, AstraZeneca Plc, Pfizer Inc, Johnson & Johnson, Arcellx Inc, Ascentage Pharma Group International, Astex Pharmaceuticals Inc, Cyclacel Pharmaceuticals Inc, and Innovent Biologics Inc.

Myelodysplastic Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update standard reports
Currency USD
$2,500

Can be used by individual purchaser only

Most Popular
$5,000

Can be shared by unlimited users within one corporate location e.g. a regional office

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Myelodysplastic Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Oncology reports
Pharmaceuticals
New
New Drug Approvals and Their Contract Manufacture - 2024 Edition
$4,995 | April 2024
Pharmaceuticals
New
Methicillin-Resistant Staphylococcus aureus (MRSA) Epidemiology Analysis and Forecast to 2033
$3,995 | April 2024
Pharmaceuticals
New
Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…
$6,995 | March 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Myelodysplastic Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Myelodysplastic Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more